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Background: Although a number of clinical and preclinical studies have demonstrated analgesic effects of
cannabinoid treatments, there are also instances when cannabinoids have had no effect or even exacerbated pain.
The observed pro-nociceptive effects appear to be due to cannabinoid-induced disinhibition of afferent synaptic
input to nociceptive circuits. To better understand how cannabinoid-mediated plasticity can have both pro- and
anti-nociceptive effects, we examined the possibility that cannabinoids differentially modulate nociceptive vs.
non-nociceptive synapses onto a shared postsynaptic target. These experiments were carried out in the central
nervous system (CNS) of the medicinal leech, in which it is possible to intracellularly record from presynaptic
nociceptive (N-cell) or pressure-sensitive (P-cell) neurons and their shared postsynaptic targets.
Results: The endocannabinoid 2-arachidonoyl glycerol (2AG) elicited significant long-lasting depression
in nociceptive (N-cell) synapses. However, non-nociceptive (P-cell) synapses were potentiated following 2AG
treatment. 2AG-induced potentiation of non-nociceptive synapses was blocked by the TRPV antagonist
SB366791, suggesting involvement of the same TRPV-like receptor that has already been shown to mediate
endocannabinoid-dependent depression in nociceptive inputs. Treatment with the GABA receptor antagonist
bicuculline also blocked 2AG-induced potentiation, consistent with the idea that increased synaptic signaling
was the result of endocannabinoid-mediated disinhibition. Interestingly, while bicuculline by itself increased
non-nociceptive synaptic transmission, nociceptive synapses were depressed by this GABA receptor antagonist
indicating that nociceptive synapses were actually excited by GABAergic input. Consistent with these observations,
GABA application depolarized the nociceptive afferent and hyperpolarized the non-nociceptive afferent.
Conclusions: These findings show that endocannabinoids can differentially modulate nociceptive vs.
non-nociceptive synapses and that GABAergic regulation of these synapses plays an important role in
determining whether endocannabinoids have a potentiating or depressing effect.
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Endogenous cannabinoids (endocannabinoids or eCBs),
such as anandamide and 2-arachidonoyl glycerol (2AG),
are lipid neurotransmitters found throughout the central
nervous system of both vertebrates and invertebrates that
modulate a number of behavioral processes including
appetite, cognition, emotion, sensory processing and
nociception [1,2]. In many regions of the CNS, the pri-
mary physiological effect of eCBs is depression of synaptic
transmission that can be short-term (milliseconds to* Correspondence: bburrell@usd.edu
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reproduction in any medium, provided the orseconds) or long-term (tens of minutes to hours) [3]. eCBs
can depress both excitatory and inhibitory synapses, so
that from a functional standpoint these neurotransmitters
can be bi-directional modulators of neural circuits depen-
ding on whether there is depression of an excitatory path-
way (decreasing circuit activity) or depression of an
inhibitory pathway (increasing circuit activity via disin-
hibition). This is a significant consideration in terms of
development of eCB-based pharmacotherapies because
treatments focused on depression of excitatory synapses
may produce undesired effects through depression of
inhibitory synapses. The importance of this issue has
become apparent in the potential use of cannabinoid-
based treatments for chronic pain. In a recent study,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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glycinergic inhibitory signaling in the spinal cord that
contributed to secondary hyperalgesia due to disinhi-
bition of afferent synaptic input to spinal pain circuits
[4]. However, it was not known whether this pro-algesic
effect occurred at the nociceptive afferent synapses (Aδ
and C fibers) or at non-nociceptive afferent synapses
(Aβ fibers). Non-nociceptive afferents can have input to
pain circuits in the spinal cord as a result of central
sensitization and can potentially contribute to chronic
pain conditions [5].
To address this issue, the CNS of the medicinal leech
(Hirudo verbana) was used to test the effects of eCBs on
nociceptive vs. non-nociceptive synapses. The leech is a
useful model system in which to carry out these studies
because it has a well-defined nervous system in which
the identity of nociceptive and non-nociceptive neurons
are known as well as their synaptic targets. The leech
CNS consists of a chain of segmentally-arranged ganglia,
each with its own set of sensory, motor and local and
intersegmental interneurons. Similar to mechanosen-
sation in mammals, the leech receives input from three
distinct catergories of sensory neurons innervating the
skin: rapidly-adapting touch cells (T-cells), slow-adap-
ting pressure-sensitive neurons (P-cells) and two types
of nociceptive neurons (N-cells), one that is a mechan-
ical and the other a polymodal nociceptor that responds
to mechanical, thermal and chemical stimuli [6-8]. The
cell bodies for each type of somatosensory neuron are
located in the segmental ganglia and can be easily identi-
fied based on their size, position within each ganglion
(see Figure 1) and electrophysiological properties. Fur-
thermore, a number of the postsynaptic targets of these
afferents are known and in many cases are shared by allFigure 1 Ventral and dorsal aspects of a single ganglion from the lee
outlined in red (N-cell), green (P-cell), blue (AP-cell) and brown (L motor nethree types of sensory neurons [9]. Therefore, it is pos-
sible to selectively carry out dual intracellular record-
ings of both the pre- and postsynaptic neurons in these
nociceptive vs. non-nociceptive synapses. This capacity
to carry out detailed studies from identifiable neurons
and their synapses has already been used to develop a
detailed understanding the cellular signal mechanisms
mediating eCB-dependent depression of nociceptive
synapses in the leech [10-12].
The leech CNS is known to contain the eCBs 2AG
and anandamide with 2AG being the more abundant
transmitter [14]. Furthermore, 2AG has been shown to
mediate long-term depression (LTD) in leech nociceptive
synapses that are remarkably similar to mammalian
eCB-LTD in terms of cellular mechanisms [3,10]. Like
other protostomal invertebrates, the leech lacks ortho-
logues to the vertebrate cannabinoid receptors CB1 and
CB2 [2]. However, transient potential receptor vanilloid
(TRPV) channels can also act as cannabinoid receptors
[15-18] and previous pharmacological studies from our
laboratory indicate that a leech TRPV-like receptor
mediates 2AG-induced depression in nociceptive synap-
ses [10].
In the present study, the effects of 2AG on nociceptive
synapses (those made by the N-cells) versus non-no-
ciceptive synapses (those made by the P-cells) were
compared in which both afferent types converged on the
same postsynaptic target (the longitudinal or “L” motor
neuron). 2AG elicited depression at nociceptive synapses,
but potentiation at non-nociceptive synapses. This 2AG-
mediated potentiation of the non-nociceptive synapses
required functional GABA receptors, indicating eCB-
induced increases in synaptic signaling were the result of
synaptic disinhibition.ch CNS (modified from [13]). Neurons used in this study have been
uron).
Figure 2 Differential endocannabinoid modulation of
nociceptive vs. non-nociceptive synapses. (A) Sample traces
from experiments using nociceptive (N-to-L, left) and non-
nociceptive (P-to-L, right) synapses. Top EPSP traces are from control
experiments in which pre- and post-test recordings (black and grey
traces, respectively) were made 75 mins apart without 2AG
treatment. Middle EPSP traces are from experiments in which pre-
and post-test recordings were made in 2AG-treated ganglia. Bottom
traces are action potentials from the presynaptic N-cell (left) or P-cell
(right). Vertical calibration bar is 2mV EPSP traces and 50 mV for
action potential traces. Horizontal calibration bar is 50 msec for all.
(B) Bar graph showing that 2AG depressed the N-to-L synapse, but
potentiated the P-to-L synapse. (C) Bar graph showing that 2AG
depressed the N-to-AP synapse, but potentiated the P-to-AP
synapse. Asterisks indicate statistically significant difference relative
to the vehicle control group (see Results section for details).
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Effects of 2AG on nociceptive vs. non-nociceptive
synapses
For most of the experiments in this study, excitatory post-
synaptic potentials (EPSPs) were recorded from synapses
made by either the lateral (polymodal) nociceptive (N-)
cell or one of the pressure-sensitive (P-) cells onto the L
motor neuron (Figure 1). The L motor neuron innervates
the longitudinal muscles and is active during the defensive
withdrawal reflex, whole-body shortening [19]. This motor
neuron receives monosynaptic, glutamatergic input from
the both the P- and N-cells [10,20]. Previous studies have
shown that 2AG (60 μM for 15 mins) induced LTD in
nociceptive synapses made by the lateral N-cell onto the L
motor neuron (Figure 2A, B; data re-presented from [10];
t=6.45, p≤0.0001, n=5). In contrast, the non-nociceptive
P-to-L synapse was actually potentiated 1 hr following
bath application of 60–100 μM 2AG for 15 min (N=10)
relative to control synapses in which 2AG application was
omitted (Figure 2A, B; t=3.37, p≤0.005, n=10). Potenti-
ation did not appear to be due to postsynaptic changes in
intrinsic excitability given that input resistance (IR) in the
L motor neuron was unchanged (post-test IR was 100.6
±2.9% of pre-test levels in the 2AG-treated group and
103.2±3.7% in the vehicle control group). The effects of 60
and 100 μM 2AG on the P-to-L synapse were indis-
tinguishable with 60 μM 2AG producing a 48.2±10.4%
increase (n=4) and 100 μM producing a 56.1±22.1% (n=6)
increase in EPSP amplitude (independent t-test p=0.79);
therefore the data from these two concentrations were
combined. N-to-L synapses treated with 100 μM 2AG still
underwent depression (64.6±10.3% of initial EPSP ampli-
tude; n=3) that was no different from the effects observed
at 60 μM (63±4%; independent t-test p=0.87). These
results indicate that the potentiating effect of 100 μM
2AG on the non-nociceptive synapse was not a conse-
quence of the concentration of 2AG used.
To determine if these opposing effects of 2AG were a
feature of other nociceptive and non-nociceptive synapses,
N- and P-cell input to the anterior pagoda (AP) cell was
also examined. Although the function of the AP cell is not
known, the monosynaptic, glutamatergic P-to-AP synap-
ses have been used to study a variety of forms of synaptic
plasticity in the leech [21-25]. However, the N-to-AP syn-
apse had not been previously characterized and this was
done prior to conducting the 2AG experiments. In general
the N-to-AP synapse was quite similar to the N-to-L con-
nection. N-to-AP was substantially reduced by CNQX
(20 μM) indicating glutamatergic transmission (Additional
file 1: Figure S1A). In experiments with high MgCl2 saline
(15 mM), which blocked all chemical synaptic transmis-
sion [20], the majority of the N-to-AP EPSP was elimi-
nated except for a small (<1 mV) early component that
appeared to be a rectifying electrical synapse between the
Figure 3 Role of the leech TRPV-like receptor and GABA during
2AG-mediated synaptic potentiation. (A) The TRPV1 antagonist,
SB366791 (10 μM), prevents potentiation of the non-nociceptive
P-to-L synapses that is normally observed following 2AG treatment.
Asterisks indicate statistically significant difference relative to the
vehicle control group (see Results section for details). (B) Role of
GABA signaling during 2AG-mediated synaptic potentiation.
Pretreatment of synapses with the GABA receptor antagonist
bicuculline (100 μM), prevented 2AG-induced potentiation of the
non-nociceptive N-to-L synapse. Asterisks indicate statistically
significant difference relative to the vehicle control group
(see Results section for details).
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tive electrical EPSP was also observed in the CNQX ex-
periments. Experiments with high divalent saline (18 mM
MgCl2/15 mM CaCl2) eliminated later components of the
N-to-AP EPSP indicating the presence of polysynaptic
elements (Additional file 1: Figure S1C). While positive
current associated with the N-cell action potential did
propagate to the AP via electrical coupling, negative
current injected into the N-cell did not spread to the AP
(data not shown). Interestingly, evidence of electrical
coupling was also observed in the AP-to-N direction.
Injection of 500 msec current pulses showed that negative
current, but not positive current, could spread from the
AP to the N-cell (Additional file 1: Figure S1D).
In terms of eCB modulation, 2AG (100 μM) depressed
N-to-AP synapses (n=9 and 5 respectively; t=2.91,
p≤0.05), but potentiated P-to-AP synapses relative to
controls (n=6 and 5 respectively; t=2.36, p≤0.05) iden-
tical to N- and P-cell inputs to the L motor neuron
(Figure 2C). No obvious changes in postsynaptic IR were
observed during the P-to-AP (2AG group=111.5±3.2%,
control=106.8±5.6) or N-to-AP (2AG group=104.6±3.8%,
control=97.7±6.2%) synapses.
To test whether 2AG-induced potentiation of the non-
nociceptive P-cell synapses is mediated by a TRPV-like
receptor, experiments were carried out using the selec-
tive TRPV1 antagonist SB366791 (10 μM), which blocks
eCB-mediated LTD in leech nociceptive synapses [10].
When SB366791 was co-applied with 2AG, potentiation
of the non-nociceptive P-to-L synapse was prevented
(Figure 3A; n=6). Application of SB366791 alone had no
effect on the P-to-L EPSP (N=5). One-way ANOVA of
the 2AG+SB366791, SB366791, 2AG and vehicle control
groups showed a significant treatment effect (F2,18=6.01,
p≤0.05). Post-hoc analysis showed that the 2AG group
was statistically different from the control group
(p≤0.05), but that the 2AG+SB366791 and SB366791
groups were not. Postsynaptic IR was unchanged in
the 2AG+SB366791 (110.1±4.6% of pre-test levels),
SB366791-only (101.7±5.6%) and vehicle control groups
(101±3.9%; n=6). These findings indicate that the differ-
ence in the effects of 2AG on nociceptive vs. non-
nociceptive synapses is not due to activation of different
endocannabinoid receptor.
Role of GABA receptors during 2AG-induced potentiation
eCBs are known to depress inhibitory synaptic transmis-
sion and eCB-induced disinhibition has been shown to
increase synaptic signaling within spinal nociceptive cir-
cuits, although the identity of the presynaptic input(s)
being enhanced was not known [4]. Therefore, we exam-
ined the potential role of GABA-A receptors during
2AG-induced potentiation of the non-nociceptive syn-
apse in the leech. The leech CNS contains GABAergicneurons and the GABA-A receptor antagonist
bicuculline has been shown to disinhibit other circuits
that utilize P-cell input [26-28]. To test whether func-
tional GABA-A receptors are required for 2AG-
mediated potentiation, ganglia were pre-treated with
bicuculline (100 μM) followed by the pre-test measure-
ments of the P-to-L EPSP, 15 min application of 2AG,
washout for 60 mins and finally post-test EPSP measure-
ments. The 2AG treatment that normally produces po-
tentiation was blocked in the non-nociceptive P-to-L
synapses that had undergone bicuculline+2AG treatment
(Figure 3B; n=5). P-to-L synapses that were pre-treated
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were unchanged between the pre- and post-tests (Figure
3B, n=5). One-way ANOVA of the 2AG+bicuculline,
bicuculline, 2AG and vehicle control group showed a
significant effect of treatment (F2,24=7.13, p≤0.005). Post-
hoc analysis showed that the 2AG group was statistically
different from the control group (p<0.01) and that the
2AG+bicuculline and bicuculline groups were not. No
change in postsynaptic input resistance was observed in
the 2AG+bicuculline (104±4.4%) or bicuculline only group
(96±4.6%). These findings support the hypothesis that
2AG-induced potentiation of non-nociceptive synapses is
mediated by disinhibition as a result of a decrease in
GABAergic input.
If 2AG potentiates non-nociceptive synapses due to a
decrease in GABAergic input, why are nociceptive
synapses not similarly disinhibited? GABA has been
observed to depolarize the lateral N-cells used in these
experiments [29] so it is possible that GABA excites
rather than inhibits the nociceptive synapse. To confirm
this earlier finding and to determine what effect GABAFigure 4 Opposing effects of GABA on nociceptive vs. non-nociceptiv
and non-nociceptive (P-cell) afferents to GABA. GABA elicited depolarizatio
respectively, 2 mV/500 msec and 0.5 mV/1000 msec). Both responses were
and this decrease was not observed when a 15 mins saline treatment was
the nociceptive (N-to-L) synapse, but enhances the non-nociceptive (P-to-L
msec. Asterisks indicate statistically significant difference relative to the vehhas on the P-cell, intracellular recordings of the N- and
P-cells were made in response to GABA delivered via
puffer electrodes. GABA reliably elicited depolarization in
the lateral N-cells, consistent with earlier findings, but
produced hyperpolarization in the P-cells (Figure 4A).
Both the N-cell (n=6) and P-cell (n=3) responses were
significantly inhibited following 15 min bath-application
of 100 μM bicuculline (Figure 4A; N-cell, paired t-test
t=8.80, p≤0.001; P-cell, t=4.56, p≤0.05). No changes in N-
cell (n=5) or P-cell (n=5) GABA response were observed
in control experiments in which responses were recorded
prior to and then 15 mins following treatment with nor-
mal saline (Figure 4A; N-cell, paired t-test t=1.65, p>0.05;
P-cell, t=0.81, p>0.05).
Next, P-to-L and N-to-L EPSPs were recorded prior to
and then during acute bicuculline treatment (100 μM
for 10–15 mins). As expected, the P-to-L EPSP ampli-
tude increased during bicuculline treatment (n=7) com-
pared to control synapses (n=5); that is, disinhibition of
the non-nociceptive synapse was observed (Figure 4B;
t=2.71, p≤0.05). However, bicuculline treatment actuallye afferents and their synapses. (A) Response of nociceptive (N-cell)
n in the N-cells and hyperpolarization in the P-cells (scale bars are,
inhibited by subsequent treatment 15 mins with bicuculline (100 μM)
used in place of bicuculline. (B) Acute bicuculline treatment depresses
) synapse. Scale bars are, respectively, 2 mV/50 msec and 5 mV/50
icle control group (see Results section for details).
Figure 5 Hypothetical model for opposing effects of 2AG on
nociceptive (N) versus non-nociceptive (P) synapses. Both N-
and P-cells have input onto the same postsynaptic targets (in this
example, the L motor neuron) via glutamatergic synapses. Based on
previous studies [10], 2AG directly depresses the nociceptive synapse
via a TRPV-like receptor that reduces presynaptic neurotransmitter
release. In the present study, 2AG was observed to potentiate the
non-nociceptive synapse via an indirect mechanism in which the
eCB reduces inhibitory input from an unknown GABAergic
interneuron (int). This 2AG-mediated disinhibition appears to be
mediated by the TRPV-like receptor as well. Nociceptive synapses are
“protected” from this disinhibitory because they are depolarized by
GABA. The same GABAergic interneuron is shown to act on both
the N- and P-cells for diagrammatic purposes and it is not known
whether these afferents receive GABAergic input from a common
source or from distinct interneurons.
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pared to control synapses (n=5) suggesting that GABA
has a tonic excitatory effect on this nociceptive synapse
(Figure 4B; t=2.35, p≤0.05). No change in postsynaptic
input resistance was observed during either the P-to-L
synapse (bicuculline=96.7±4.9, control=105.7±6.4%) or
N-to-L synapse (bicuculline=107.7±2.2%, control=98.7
±3%) experiments. These findings are consistent with
the idea that this nociceptive synapse does not undergo
2AG-induced disinhibition, at least in part, because the
presynaptic neuron is excited, not inhibited, by GABA.
Discussion
The endocannabinoid 2AG was found to differentially
modulate nociceptive vs. non-nociceptive synapses in
the leech, depressing the former and potentiating the
latter. 2AG-induced potentiation of non-nociceptive
synapses was blocked by the TRPV1 inhibitor SB366791,
suggesting that the involvement of a TRPV-like receptor.
In mammals, the TRPV1 receptor has been shown to be
an important cannabinoid receptor that mediates synap-
tic depression in a variety of brain regions [16-18,30].
Protostomal invertebrates lack orthologues to the verte-
brate CB1/CB2 receptors [2] and we have previously
proposed that TRP channels, such as TRPV, may re-
present the earliest endocannabinoid receptors in the
animal kingdom [10,11]. One critical difference between
the nociceptive and non-nociceptive synapses is that
while N-cells appear to possess TRPV-like receptors, P-
cells do not [8]. This would indicate that the effects of
2AG on P-cell synapses are indirect and mediated by an
unknown, 2AG-sensitive neuron. It is unlikely that the
postsynaptic L motor neuron is being directly modulated
by 2AG because it too lacks TRPV-like receptors,
although it does appear to be capable of synthesizing
2AG [10].
Potentiation of non-nociceptive synapses was blocked
when the GABA-A receptor antagonist bicuculline was
applied. Bicuculline by itself was found to enhance non-
nociceptive synaptic transmission indicating that this
synapse is tonically regulated by inhibitory GABAergic
input, consistent with previous studies of P-cell signaling
[26,27]. From these results, we propose a model in
which 2AG depresses inhibitory synaptic transmission
from an unknown GABAergic neuron(s) onto P-cell
synapses resulting in disinhibition of these non-
nociceptive synapses (see Figure 5). When GABAergic
input was reduced by bicuculline pre-treatment, the
ability of 2AG to elicit potentiation via this proposed
disinhibition was occluded. It should be noted that the
specificity of both SB366791 and bicuculline as antago-
nists has not been directly tested on isolated leech
versions of the TRPV and GABA receptors. Therefore,
the possibility exists that the effects of both of thesepharmacological agents are due to actions not associated
with either of these receptors.
The fact that 2AG did not potentiate nociceptive
synapses appears to be due to differences in how GABA
affects nociceptive vs. non-nociceptive synapses (Figure 5).
The same bicuculline treatment that disinhibited non-
nociceptive synapses actually decreased N-cell synaptic
transmission suggesting that GABA has an excitatory
effect on these nociceptive synapses. This is supported by
the observation that GABA applied to the soma depo-
larizes the lateral N-cell [29]. In the present study, the
ability of GABA to depolarize the N-cell was replicated
and extended by showing that this GABA-induced depo-
larization could be inhibited by bicuculline. Furthermore,
direct application of GABA to the P-cell was found to
elicit hyperpolarization that was also inhibited by bicu-
culline. The excitatory effects of GABA on the N-cell are
likely the result of elevated intracellular Cl- concentration
so that the Cl- equilibrium potential is depolarized relative
to the resting potential. Thus, activation of ionotropic
GABA receptors would cause a Cl- efflux, depolarizing the
N-cell. It well-established that GABA can depolarize noci-
ceptive afferents in the spinal cord as a result of elevated
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(ECl) [31]. GABA-mediated depolarization has been shown
to increase synaptic transmission in both the brain and
the spinal cord circuits [32-35], although there are also
instances when GABA-mediated depolarization inhibits
synaptic transmission via current shunts or Na+ channel
inactivation [31,35].
It is not clear whether GABAergic modulation of the
P-to-L synapse is being exerted on the presynaptic or
postsynaptic neuron (or both). Leech motor neurons do
receive inhibitory GABAergic input [26,36], but no
changes in postsynaptic input resistance were observed
during any of the 2AG experiments, which would argue
against a postsynaptic mechanism. Furthermore, the fact
that N- and P-cell synapses onto the same postsynaptic
target (L motor neuron or AP cell), but underwent
opposite changes following 2AG treatment would also
support a presynaptic mechanism for both eCB-induced
potentiation and depression. Previous studies have been
supportive of a presynaptic mechanism mediating 2AG-
induced depression of nociceptive (N-to-L) synapse
[10,11]. Nevertheless, the possibility of localized, synapse-
specific changes in the postsynaptic neuron cannot be
eliminated and additional studies are required to further
assess the role of pre- vs. postsynaptic modulation during
eCB-mediated synaptic plasticity.
The results from this study address important issues
regarding the modulatory effects of eCB at the micro-
circuit level. It is well-established that eCBs depress
inhibitory (as well as excitatory) synaptic transmission
and that such eCB-mediated disinhibition is likely to
have important consequences in terms of neural circuit
function [16,37-42]. For example, eCB-induced disin-
hibition has been observed to lower the threshold for
initiating LTP [43-45]. However, this is the first time, to
our knowledge, that eCB-induced increases in evoked
synaptic transmission via disinhibition have been directly
observed. Furthermore, by using the well-described CNS
of the leech it was possible to observe opposing synaptic
effect of eCBs (depression vs. potentiation) on distinct
afferent inputs that converge onto a shared postsynaptic
target. This allowed us to address the issue as to why
eCB-induced disinhibition does not lead to increased
synaptic signaling in more neurons given the widespread
nature of GABAergic regulation of synaptic transmis-
sion. We found evidence that while some synapses were
sensitive to eCB-mediated disinhibition; others were
“protected” from such modulation because they were
not inhibited by GABA. In fact, GABA appeared to have
an excitatory effect on these synapses based on results
from experiments in this study and those from Sargeant
et al. [29], presumably as a result of elevated intracellular
Cl- levels. This would suggest that the Cl- gradient in
neurons plays a critical in regulating the effects of eCBson synaptic signaling. Such a mechanism has already
been suggested by Christie and Mallet [46].
These findings may contribute to understanding why
there is such conflicting evidence from both animal
model and clinical studies regarding the efficacy of
cannabinoid based analgesic therapies [46-50]. In some
clinical studies, cannabinoids were found to be ineffec-
tive and could even enhanced pain associated with
evoked mechanical stimuli resulting in mechanical
hyperalgesia or allodynia [4,46,51]. One explanation for
these pro-nociceptive effects is that eCBs have been
shown to depress inhibitory synapses in the spinal cord,
thereby disinhibiting spinal pain circuits, which contri-
butes to the development of secondary mechanical
hyperalgesia [4]. It is possible that eCBs selectively
enhance synaptic input from afferents that contribute to
mechanical hyperalgesia or allodynia, such as Aβ fibers
[5], but depress synaptic input from nociceptive affer-
ents, such as Aδ or C fibers [50]. As stated above, these
synaptic potentiation vs. depression effects of eCBs may
be due to whether GABA inhibits or excites the relevant
afferent [46]. Although the present study is focused on
changes in afferent signaling, inhibitory and excitatory
interneurons in the dorsal horn can also undergo shifts
in the ECl that lead to GABA-elicited depolarization
during neuropathic pain [52,53]. Changes in GABAergic
signaling onto these neurons may also impact how
cannabinoid-based treatments affect these nociceptive
neural circuits.
Conclusions
Nociception is a fundamental sensory process that
exhibits considerable evolutionary conservation between
vertebrates and invertebrates [54,55]. The leech, in par-
ticular, provides a useful model system in which to study
the basic physiological processes related to nociception.
It possesses afferents innervating the skin that de-
monstrate clear nociceptive properties and share many
features with vertebrate polymodal nociceptors including
a high threshold for both mechanical and thermal (>40°C)
stimuli as well as sensitivity to noxious chemical stimuli
[8]. These nociceptors are clearly distinguishable from the
lower threshold non-nociceptive mechanosensory neurons
and it is possible to carry out detailed recordings from
nociceptive vs. non-nociceptive synapses.
The findings from the present study suggest that the
effectiveness of cannabinoid-based analgesic therapies is
likely to depend on the type of nociception that is being
experienced. As already stated, there is evidence from
both preclinical and clinical studies that eCBs can have
both pro- and anti-nociceptive effects [4,46]. Interes-
tingly, there is also evidence to suggest that central
TRPV receptor activation can have opposing effects on
spinal nociceptive circuits in rodents mediating both
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persistent depression of C fiber evoked EPSPs [57-59].
Cannabinoid-based therapies may be appropriate for
conditions that result from spontaneous activity from
nociceptive afferents, such neuropathy-associated chro-
nic pain [49,60]. On the other hand, conditions that are
dominated by mechanical hyperalgesia and/or allodynia
may be insensitive to or even exacerbated by cannabinoid-
based treatments due to the potential involvement of non-
nociceptive afferents [5]. Additional studies using the
leech CNS, at both the synaptic and behavioral level, may
contribute to better understanding the pro- vs. anti-
nociceptive effects of eCBs.
Methods
Animal preparation
Leeches (Hirudo verbana) were obtained from commer-
cial suppliers (Leeches USA, Westbury, NY and Niagara
Leeches, Cheyenne, WY) and maintained in artificial
pond water (0.50g/L H2O Hirudo salt) on a 12 hour
light/dark cycle at 18°C. Ganglia were dissected and
pinned in a recording chamber with constant perfusion
of normal leech saline (≈1.5 ml/min). All dissections and
recordings were carried out in normal leech saline
(110 mM NaCl, 4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2,
5 mM NaOH, and 10 mM HEPES, pH=7.4). Drugs were
dissolved in leech saline from stock solutions and final
concentrations were made just prior to respective expe-
riments. The following drug was obtained from Tocris
(Ellisville, MO): 2-arachidonoyl glycerol (2AG). Drugs
obtained from Sigma-Aldrich (St. Louis, MO) included
CNQX, dimethyl sulfoxide (DMSO), and bicuculline.
Electrophysiology
Techniques used in this study have been described in
detail in [10]. Briefly, current clamp (bridge balanced)
intracellular recordings were carried out using sharp
glass microelectrodes (tip resistance 35–40 MΩ) made
from borosilicate capillary tubing (1.0 mm OD, 0.75 mm
ID; FHC, Bowdoinham, ME) using a horizontal puller
(Sutter Instruments P-97; Novato, CA). Microelectrodes
were filled with 3M potassium acetate. Manual micro-
positioners (Model 1480; Siskiyou Inc., Grants Pass, OR)
were used to impale individual neurons during expe-
riments. Current was delivered to electrodes using a
multi-channel programmable stimulator (STG 1004;
Multi-Channel Systems; Reutlingen, Germany) and the
signal was recorded using a bridge amplifier (BA-1S;
NPI, Tamm, Germany) and digitally converted for ana-
lysis (Axoscope; Molecular Devices, Sunnyvale, CA).
The presynaptic lateral nociceptive (N) and pressure
(P) cells and the postsynaptic longitudinal (L) motor
neuron and anterior pagoda (AP) cell were identified
based on their position with the ganglion (Figure 1), size,and characteristic electrophysiological properties (size
and shape of action potential). L motor neuron iden-
tification could be confirmed by recording from the
electrically coupled contralateral L motor neurons and
observing synchronous activity [61]. For experiments
utilizing N-to-L and P-to-L synapse recordings, the
ganglion was pinned dorsal side up so that the L motor
neurons could be located on the dorsal side along with
access to the lateral-most N- and P-cells. For N-to-AP
and P-to-AP synapse recordings, the ganglion was
pinned ventral side up. Following pre-test recordings of
the excitatory postsynaptic potentials (EPSPs), the gan-
glion was superfused with 2AG for 15 minutes and then
returned to normal saline. In vehicle control experi-
ments, 2AG was replaced with saline containing 0.01%
DMSO. After one hour, the EPSP was retested (post-
test). Separate electrode impalements of the same
presynaptic and postsynaptic neuron were made for pre-
and post-test recordings. Chronic intracellular record-
ings of these neurons were not carried out because this
results in progressive rundown of the EPSP within
10–15 mins most likely due to damage caused by move-
ments of the tissue during the electrode impalement
(there are muscle fibers and connective tissue present in
the leech CNS). Input resistance was recorded at the
pre- and post-test level and only consistent, stable
recordings were included in the data analysis (see
Results section). The peak EPSP amplitude was recorded
every 10 seconds and calculated by averaging 5–10 EPSP
(pre- or post-test) sweeps.
For N-to-AP characterization experiments, the gan-
glion was pinned ventral side up as the lateral N-cell
and AP-cell were both located on the ventral side. Treat-
ments for the set of characterization experiments (high
Mg2+ saline, high divalent saline, and CNQX) were
perfused for 10 to 15 minutes between pre-test and
post-test recordings while controls were carried out in
constant perfusion of normal leech saline. Coupling
experiments were performed by injecting single 500
msec hyperpolarizing current pulses with increasing
amounts of current into the AP- or N-cell and recording
any subsequent response from the opposite cell.
The effects of GABA on the N- and P-cells were tested
using a “puffer” electrode (a patch electrode with a re-
sistance of ≈ 5 MΩ) connected to a picospritzer. The
puffer electrode was positioned approximately 100 μm
from the N or P soma to prevent movement artifact and
a 200 msec pulse of GABA was applied at 10 psi. The
membrane potential of the P-cell was maintained at −50
mV. The membrane potential of the N-cell was main-
tained at −60 mV in order to prevent the cell from firing
when GABA was applied. The concentration of GABA
within the puffer electrode was 1 M, consistent with
similar studies in the leech by Sargent et al. [29]. This
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the substantial amount of dilution that occurred by the
time the expelled GABA reached the neuropil, which is
relatively deep in the ganglion. That responses to GABA
appear to arise from N- and P-cell processes in the
neuropil is based on the delay between the GABA puff
and the P- or N-cell response which ranged between
100–300 msec.
Post-test EPSP amplitudes and input resistance mea-
surements were normalized relative to pre-test levels
and presented as mean ± standard error. Statistical
analyses using both independent and paired t-test or
one-way analysis of variance (ANOVA) were performed
to determine main effects with Newman-Keuls post-hoc
tests to confirm the ANOVA results.Additional file
Additional file 1: Figure S1. Characterization of the lateral N-to-AP
synapse. (A) Bath-application of the non-NMDA ionotropic glutamate
receptor antagonist CNQX reduced but did not eliminate the N-to-AP
EPSP. Calibration bars are 2 mV and 100 msec. (B) Replacement of
normal leech saline with high Mg2+ (15 mM) saline reduced but did not
eliminate the N-to-AP synapse. Calibration bars are 2 mV and 50 msec.
The small, short-latency EPSP that remains following CNQX or high Mg2+
treatment is thought to be an electrical EPSP. (C) Application of high
divalent saline (HiDi; 15mM Ca2+/18 mM Mg2+) reduces the decay time
of the N-to-AP EPSP, consistent with removal of the later, polysynaptic
components of this synaptic connection. Calibration bars are 1 mV and
50 msec. (D) In addition to the electrical coupling in the N-to-AP
direction, there was also evidence of electrical coupling in the AP-to-N
direction. Negative current injected into the AP-cell was capable of
hyperpolarizing the N-cell, but positive current failed to be carried from
the AP- to N-cell. The AP cell exhibits similar negative electrical coupling
with the S interneuron (BDB unpublished observation). Calibration bars
are 20 mV and 50 msec for the AP-cell traces (left) and 1 mV and 50
msec for the N-cell traces (right).Competing interests
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